FDA says no to Novartis heart drug

Share this article:
Novartis announces good heart drug results
Novartis announces good heart drug results

The FDA hit drugmaker Novartis with a setback Friday, rejecting the company's experimental acute heart-failure drug serelaxin through a Complete Response Letter.

Novartis announced the CRL Friday, saying the US regulator wanted more efficacy information than the Phase-II and Phase-III safety and efficacy data that accompanied the filing.

Although the FDA does not have to adhere to advisory panel recommendations, Friday's news synchs with an FDA panel's March vote against the drug, which rang in at 11-0.

Novartis is not giving up on the drug, despite Friday's announcement and the European Medicines
Agency's rejection in January. Instead, the company said it will expand the data set with a patient pool that will ultimately include 6,300 patients worldwide.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...